China Universal Asset Management Company’s Harvard Bioscience HBIO Stock Holding History

China Universal Asset Management Company’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39	Closed	-$1K	–	419
2022 Q3	$1K	Buy	+39	New	+$1.29K	﹤0.01%	394

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

China Universal Asset Management Company's HBIO Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Harvard Bioscience (HBIO) in Q4 2022, closing a stake of 39 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in HBIO in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

China Universal Asset Management Company reported no remaining Harvard Bioscience position as of Q4 2022 after selling out during the quarter.
China Universal Asset Management Company sold 39 Harvard Bioscience shares in Q4 2022, an estimated $1K.
China Universal Asset Management Company first reported a position in Harvard Bioscience in Q3 2022 and held it in 1 quarter.
China Universal Asset Management Company's Harvard Bioscience position peaked at $1K in Q3 2022.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.